All In Biotech

Drug Trial Radar · NCT05938296

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

A Phase 1, Open-label Study of BS006, an Oncolytic Virus, Administered by Intratumoral Injection in Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

29

Planned (sponsor's estimate)

Start

Dec 19, 2023

Primary completion

Dec 19, 2026

Study completion Dec 19, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of BS006 in patients with advanced solid tumors.

Conditions

  • Solid Tumor

Interventions

  • BS006 InjectionDrug

    BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AE (Adverse Event) and SAE (Serious Adverse Event)Time frame: Through study completion, an average of about 1 year(a maximum treatment duration of one year)
  2. MTDTime frame: up to 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center

    Detroit, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.